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It has recently been shown that loss-of-function mutations of
the G protein-coupled receptor (GPR)54 lead to isolated hy-
pogonadotropic hypogonadism (IHH) in mice and humans.
Such mutations are thought to be rare, even within the clin-
ical IHH population, and only a handful of alleles have been
described, making further screening of IHH populations im-
perative. We examined the genes encoding GPR54 and its pu-
tative endogenous ligand, kisspeptin-1, for mutations in a co-
hort of 30 patients with normosmic HH or delayed puberty.
One subject with HH, of mixed Turkish-Cypriot and Afro-
Caribbean ancestry, was found to be a compound heterozy-
gote for two previously undescribed missense mutations in
GPR54: cysteine 223 to arginine (C223R) in the fifth trans-
membrane helix and arginine 297 to leucine (R297L) in the
third extracellular loop. Assessed in vitro using a previously
described sensitive signaling assay in cells stably expressing
GPR54, the C223R variant was found to exhibit profoundly
impaired signaling, whereas theR297L variant showed amild
reduction in ligand-stimulated activity across the ligand dose
range. These novel mutations provide further evidence that
human HH may be caused by loss-of-function mutations in
GPR54. (J Clin Endocrinol Metab 90: 1849–1855, 2005)
HUMAN GONADAL FUNCTION is under the controlof the anterior pituitary hormones LH and FSH, the
release of which is, in turn, regulated by pulsatile secretion
of hypothalamic GnRH. In the first fewweeks after birth, this
axis is functional, but by around 6 months of age, it becomes
quiescent, thus entering the juvenile pause, which persists
until puberty. The first detectable event at the initiation of
puberty is an upsurge in the amplitude of GnRH pulses,
leading to overnight LH pulsatility and subsequent matu-
ration of the rest of the axis at puberty. The mechanisms of
the childhood inhibition of GnRH release, and its eventual
reactivation, are poorly understood but appear to include
peripheral feedback suppression by sex steroids and the
actions of ill-defined intrinsic central nervous system path-
ways (1).
Genetic defects in the hypothalamo-pituitary-gonadal axis
are manifested clinically as hypogonadotropic hypogonad-
ism (HH), with either primary failure to undergo puberty or
severe delay in the process. Defects may broadly be catego-
rized into those affecting embryonic migration of GnRH-
secreting neurones, which lead to anosmia aswell asHH (e.g.
Kallmann syndrome due to KAL, or FGFR1 mutations), and
those affecting the pulsatile release or function ofGnRH from
neurones that have migrated to their normal position. Pa-
tients suffering from the latter are normosmic. Around 40%
of patients with autosomal recessive normosmic familial HH
in one series were found to have mutations in the GnRH
receptor gene, whereas only around 10–17% of sporadic
cases are thought to harbor such mutations in GNRHR (2, 3).
In the last year, the G protein-coupled receptor (GPR)54
has been shown to be a gatekeeper gene for activation of the
GnRH axis based on loss-of-function mutations in mice and
humans. In humans, loss-of-function mutations in GPR54
have been described in two consanguineous pedigrees and
two isolated subjects with HH (4, 5) (OMIM 604161). In
tandem, mice bearing homozygous targeted disruptions of
the Gpr54 gene have been found to exhibit a similar failure
of sexual maturation (5). This shows that GPR54 is required
for the normal function of this axis and suggests that the
ligand, kisspeptin-1, may act as a novel neurohormonal reg-
ulator of the GnRH axis. The latter has recently received
support from studies showing that peripheral and central
administration of kisspeptin provokes GnRH release (6–8).
We now describe the genetic screening of the GPR54 gene
as well as the KISS1 gene encoding its putative endogenous
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ligand, kisspeptin-1, in a cohort of 30 patients with normos-
mic HH, and report the clinical phenotype of a nonconsan-
guineous subject who shows compound heterozygosity for
two novel missense mutations in the GPR54 gene. We have
also documented the prevalence of single nucleotide poly-
morphisms (SNPs) in the GPR54 and KISS1 genes, one pre-
viously undescribed, in both the study population and a
Caucasian control population.
Subjects and Methods
Subjects
Subjects for genetic screening were recruited from the clinics at Great
Ormond Street Hospital (London, UK) and Addenbrooke’s Hospital
(Cambridge, UK). Informed consent was obtained according to proce-
dures approved by the local research ethics committee of each institu-
tion. Patient characteristics are outlined in Table 1. Isolated HH was
defined as inappropriately low gonadotropin levels together with pre-
pubertal concentrations of sex steroids. It was deemed idiopathic in
which no family history of the condition was apparent, and congenital
in which undescended testes with or without small penis were noted at
birth. Constitutional delay of puberty (CDP) was defined as the absence
of signs of puberty at 14 yr of age in boys, this being described as severe
if signs were still not apparent at 15 yr. All patients were reportedly
normosmic, had otherwise normal anterior pituitary function and no
midline facial defects, and showed no evidence of structural brain pa-
thology, where assessed. In all but three cases, the coding sequence of
the GnRHR gene had been sequenced and found to be normal.
TheCaucasian control population usedwas derived from theMedical
Research Council Ely Study cohort, recruited from a population sam-
pling frame with a high response rate (74%), making it representative of
an ethnically homogeneous Caucasian population in this area of Eastern
England (9, 10). In addition, 50Afro-Caribbean control subjectswere also
selected from an independently assembled cohort used in a study of the
genetics of obesity. This group was entirely unselected with respect to
reproductive and gonadal function, as was a group of 45 Turkish control
subjects recruited as part of studies into obesity and renal tubular
disease.
Genetic screening
GenomicDNAwas isolated fromwhole blood using aQIAamp blood
kit (Qiagen, Crawley, UK), and amplified using a GenomiPhi DNA
amplification kit (Amersham Biosciences, Chalfont, UK). PCR was per-
formed using BioTaq (Bioline, London, UK) and carried out as recom-
mended by themanufacturer, with addition of dimethylsulfoxidewhere
indicated. Thirty-five cycles (60 sec at 95 C, 60 sec at the annealing
temperature, and 60 sec at 72 C) were performed using a PTC-225 Peltier
thermal cycler (MJ Research, Watertown, MA). PCR products were
verified electrophoretically and sequenced using ABI BigDye Termina-
tor (version 3.1) reagents with electrophoresis on an ABI Prism 3100-
Avant genetic analyzer (PE Applied Biosystems, Foster City, CA). Sub-
sequent sequence analysis was performed using Sequencher software
(Gene Codes, Ann Arbor, MI). Primers, annealing temperatures, and
concentrations of MgCl2 and dimethylsulfoxide used for PCR are de-
tailed in Table 2, together with sequencing primers where different.
To distinguish compound heterozygosity for the two mutations de-
scribed from heterozygosity for a double mutation, the GPR54 exon 4
forwardprimer and exon 5 reverse primer (Table 2)were used to amplify
exons 4 and 5 and the intervening intron using reaction conditions as for
exon 5. The PCR product was then cloned into a pGEM-T Easy Vector
(Promega, Southampton, UK), and 16 separate clones were sequenced.
Creation of GPR54 mutant alleles and in vitro
functional assays
Wild-type human GPR54 was amplified from human brain cDNA
(Origene Technologies, Rockville, MD) using the GC-Rich PCR kit
(Roche Diagnostics, Lewes, UK). The 5 primer TAATCAAAGCTTGC-
GATGCACACCGTGGCTACGTC and 3 primer ACATTAGGATCCT-
CACTTATCGTCGTCATCCTTGTAATCGAGAGGGGCGTTGTC-
CTCC (incorporating a 3 sequence encoding the FLAG epitope tag)
were used. The resulting product was cloned into pCRBlunt (Invitro-
gen, Renfrew, UK) and sequence verified. Stable cell lines expressing
the wild-type GPR54-FLAG or one of the two mutant species described
were then created using the Flp-In system (Invitrogen). In brief, the
GPR54-FLAG was subcloned into pcDNA5/FRT and the point mutat-
ions were introduced using a QuikChange site-directed mutagenesis kit
(Stratagene, La Jolla, CA) according to the manufacturer’s instructions.
All the resulting constructs were verified by direct sequencing. The
Flp-In-293 cell line (Invitrogen) was maintained in DMEM
supplemented with 10% Fetal Clone III (Hyclone, Cramlington, UK)
and 2 mm l-glutamine. To create stable GPR54-expressing cell lines,
Flp-In-293 cells were cotransfected with the pcDNA5/FRT-GPR54-
FLAG constructs and the Flp recombinase-expressing plasmid pOG44
using polyfect (Qiagen), with subsequent selection by hygromycin B.
Transcription of the inserted alleles was confirmed by RT-PCR (data
not shown).
To assess signal transduction by the wild-type and mutant receptors,
a sensitive calciummobilization signaling assay was used as previously
described (11–13), with calcium flux in response to kisspeptin-1 112–121
(Phoenix Pharmaceuticals, Belmont, CA) measured on a FlexStation
using a FLIPR calcium assay kit (both from Molecular Devices, Sunny-
vale, CA) in response to Kisspeptin-1 112–121 (Phoenix Pharmaceuti-
cals). Data were analyzed using SoftMax Pro software (Molecular De-
vices). Experiments were performed in duplicate on 2 consecutive days,
and sds are indicated.
Results
Genetic screening
Sequencing of the coding regions of the GPR54 (GenBank
accession no. AY253981) and KISS1 (GenBank accession no.
AY117143) genes in all 30 patients revealed the presence of
two previously described SNPs in theGPR54 gene, and three
previously described SNPs, one novel SNP, and one previ-
ously described insertional polymorphism in theKISS1 gene.
The details of these common variants, and their frequency in
both the study population and 180 Caucasian control alleles
are shown in Table 3.
One boy with isolated HH was found to harbor two rare
sequence variants in the GPR54 gene (Fig. 1): the first, a
transversion c.667TC in exon 4, results in substitution of a
cysteine near the cytoplasmic end of the fifth transmembrane
-helix for arginine (C223R), whereas the second, a trans-
version c.891GT in exon 5, leads to the substitution of an
arginine in the third extracellular loop for leucine (R297L).
Cloning a section of the GPR54 gene encompassing exons 4
TABLE 1. Description of cohort studied
Diagnosis Sex Ethnicity
Idiopathic IHH 11 Malesa
3 Females
12 Caucasian
1 Turkish
1 Indian
1 Turkish/Jamaican
Familial IHH 1 Male
2 Females
1 Caucasian
1 Sri Lankan
1 Sudanese
Familial IHH or CDP 2 Males
0 Females
2 Caucasian
Familial CDP 8 Males
0 Females
8 Caucasian
Idiopathic severe CDP 3 Males
0 Females
3 Caucasian
a Includes proband described.
IHH, Isolated HH; Familial IHH or CDP, families where one
sibling has HH and another has CDP within the same generation.
1850 J Clin Endocrinol Metab, March 2005, 90(3):1849–1855 Semple et al. • Hypogonadism due to GPR54 Mutations
and 5 and the intervening intron from the genomic DNA of
the proband established that he was a compound heterozy-
gote for these two changes. The cysteine at position 223 is
highly conserved in mouse, rat, zebrafish, and pufferfish,
whereas R297 is conserved in mouse and rat but not in
zebrafish or pufferfish. Neither variant was detected in 180
Caucasian control chromosomes. The proband’s mother and
father were of Turkish-Cypriot and Jamaican descent, re-
spectively. Only his mother and younger brother were avail-
able for further study, and both were found to be heterozy-
gous for the R297L variant but homozygous wild-type with
respect to C223. The C223R variant was thus most likely
inherited from his father, although de novo mutation cannot
be ruled out. Screening of 100 control Afro-Caribbean alleles
failed to reveal any further C223R changes, whereas R297L
was not detected on screening 90 control Turkish alleles.
Case history
The proband (46, XY, birth weight 2.98 kg) was born at
term after an uneventful pregnancy. He was noted to have
a micropenis and undescended testes at birth, and serum
gonadotropins were undetectable at 2 months of age (LH 
0.5 mIU/ml, FSH 0.5 mIU/ml). His penis grew reasonably
in response to three injections of depot testosterone, but
whereas his right testis was identified in the scrotum, his left
testis remained undescended.
At 15 months of age, he was admitted for further inves-
tigation of anterior pituitary function. His height/lengthwas
progressing consistently along the 50th percentile and
weight along the 25th percentile. He had a normal GH re-
sponse to glucagon stimulation [2.1 (basal) to 30.5 ng/ml
(peak) (6.2–91.5 mU/liter; North-East Thames Radio-
Immuno Assay, cut-off for the diagnosis of GH deficiency,
11.7 ng/ml]. He had a normal cortisol response to glucagon
stimulation [19.8–47.0g/dl (554–1317 nmol/liter)], normal
free T4 [1.37 g/dl (17.5 nmol/liter)] and normal TSH re-
sponse to TRH stimulation (0.5–7.3 mU/liter). He had nor-
mal basal prolactin, and undetectable basal gonadotrophins
(LH  0.5 mIU/ml, FSH  0.5 mIU/ml). Results of a 3-d
human chorionic gonadotropin (hCG) stimulation test (1000
IU daily) showed a limited testosterone response to stimu-
lation (Table 4A). An ultrasound scan at this time identified
both testes and bilateral hydroceles. The right testis was soft,
measured 9 6 10mm, andwaswithin the scrotal sac. The
left testis had a maximum diameter of 7 mm and was iden-
tified at the left inguinal ring. A prolonged course of hCG
stimulation produced some increase in penile size but failed
to stimulate descent of the left testis. Therefore, herniotomy
and orchidopexy of a very small left testis were performed.
His progress during childhood was uneventful. However,
he showed progressive weight gain and linear growth from
the age of 3.5 yr so that by 9.7 yr of age, he was relatively tall
(height 148.6 cm,  97th percentile; parental target height
25th percentile) and heavy (weight 49.9 kg,  97th percen-
tile) but with a small penis and testes. Repeat endocrine
evaluation at 10 yr of age showed a poor gonadotrophin
response to LHRH stimulation (Table 4B) and suboptimal
testosterone response to 3 wk stimulation with hCG (1000 IU
twice weekly) (Table 4C). He was therefore started electively
on low-dose testosterone replacement to induce puberty. No
neuroimaging was performed.
The proband’s mother, who was heterozygous for R297L,
had experienced menarche at 11 yr of age. She has regular
TABLE 3. Prevalence of common sequence variants in GPR54
and KISS1
dbSNP ID SNP AA change
Cohort
frequency
(%)
Control
frequency
(%)
A. GPR54
rs8111938 615AC None 1.5 0
rs350132 1091TA H364L 23 28
rs3746147 1155GA None 0 0
B. KISS1
rs12998 207GA E20K 4.7 4.2
256AG Q36R 9.4 4.2
rs1132112 287CG None 0 0
rs4889 391CG P81R 36 13.9
565566insA Omits 7AA 76 85
AA, Amino acid; Freq., frequency.
TABLE 2. Primers and reaction conditions used for sequencing
Gene Exon Primers (5–3) [Mg2]/mM %DMSO Tm
GPR54 1 F: TTC CTG AGT TCC ACA GGC GCA 1.5 66
Ra: AGG TTT CCA TGT GCC ACA CTC
seq: AGG GAA AAG ATT CGA CGT TGG
2 Fa: GCC CAG CGC CCG CGC ATC 1.0 5 70
R: GTC CCC AAG TGC GCC CTC TC
3 F: CAG GCT CCC AAC CGC GCA G 1.0 8 64
Ra: CGT GTC CGC CTT CTC CCG TG
4 Fa: TGG AAA ATG GGC GCA ATA GCT 1.5 66
R: TGA AGG TGG TTA GAC GAA AGG
5 Fa: GCC TTT CGT CTA ACC ACC TTC 1.5 5 66
Ra: GGA GCC GCT CGG ATT CCC AC
seq1: TTA AGA CCT GGG CTC ACT GC
seq2: AGC ACC AGG AAC AGC TGG ATG
KISS1 2 Fa: TCT TGG AGG ACT GTC CCT TTT G 1.5 66
Ra: TTG CAA CAA CCC ACT TGC TCC C
3 Fa: ATG GGA TGA CAG GAG GTG TTG 1.5 66
R: ACC ATC CAT TGA GGA TGG AAG
seq: AGG AGT TCC AGT TGT AGT TCG
Tm, Annealing temperature (Centigrade); seq, sequencing primer only; DMSO, dimethyl sulfoxide.
a PCR primers also used for sequencing.
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menstrual cycles and detectable gonadotropins (LH 7.2
mIU/ml, FSH 8.3 mIU/ml). His father is believed to have
normal reproductive function but was not available for test-
ing. His younger brother, heterozygous for R297L but ho-
mozygous wild-type for C223 had normal genitalia and de-
scended testes at birth. Of note, there was no known family
history of hypogonadism or infertility in the father’s eight
siblings.
Characterization of mutant GPR54 function
Using the proprietary Flp-In system, isogenic cell lines
stably expressing either wild-type GPR54 or one of the two
mutant GPR54s at the same level of transcription were gen-
erated. A sensitive fluorometric calcium mobilization assay
was then used as described to assess the response of each
GPR54 species to the kisspeptin 112–121 decapeptide, pre-
viously established to be a potent agonist for GPR54 (12, 14).
In our hands (Fig. 2), this assay is highly sensitive for de-
tecting GPR54 activity: calcium flux above baseline for wild-
type GPR54 is detectable at subnanomolar concentrations of
ligand, with maximal flux achieved at around 100 nm.
The EC50 of the wild-type receptor was determined from
20 independent measurements. The (arithmetic) mean EC50
is 3.20 nm (lower 95% confidence interval 1.99 nm, upper 95%
confidence interval 4.41 nm, sem 0.56 nm). The range of EC50s
was 0.2–9.8 nm. The C223Rmutantwas profoundly impaired
in its signaling capability with an EC50 of 200 nm and max-
imal activity around 20% of wild-type GPR54. The function
of R297L was only mildly affected, with a measured EC50 of
7 nm and a maximal activity of 85% of wild type (Fig. 2). A
one-sample t test suggests this EC50 difference is significant,
with P  0.0001 and t  6.6. Kolmogorov-Smirnoff deter-
FIG. 1. Rare GPR54 sequence variants
found in propositus. TM, Transmem-
brane  helix.
TABLE 4. Results of dynamic endocrine testing
A. hCG stimulation test at 15 months
Pre-hCG Day 3 post-hCG
DHEA-S [g/liter (mol/liter)] 385 (1.0) 385 (1.0)
Androstenedione [ng/ml (nmol/liter)] 0.17 (0.6) 0.17 (0.6)
Testosterone [ng/ml (nmol/liter)] 0.15 (0.5) 0.45 (1.5)
B. LHRH stimulation test at 10 yr
0 min 20 min 60 min
LH (IU/liter) 0.7 1.0 0.7
FSH (IU/liter) 0.2 1.1 1.8
C. hCG stimulation test at 10 yr
Pre-hCG Day 3 post-hCG Day 21 post-hCG
DHEA-S [g/liter (mol/liter)] 1001 (2.6) 905 (2.35) 1220 (3.17)
Androstenedione [ng/ml (nmol/liter)] 1.0 (3.6) 1.2 (4.1) 1.7 (5.8)
Testosterone [ng/ml (nmol/liter)] 0.21 (0.7) 0.3 (1.0) 1.4 (4.6)
Dihydrotestosterone [ng/ml (nmol/liter)] 0.04 (0.12) 0.04 (0.12) N/A
All injections were supplied by the hospital and administered under supervision. DHEA-S, Dehydroepiandrosterone sulfate; N/A, not
available.
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mination of skewedness and kurtosis shows the control data
fit a normal distribution, so a parametric t test is appropriate.
Discussion
Human GPR54 is a G protein-coupled receptor with ho-
mology to the family of galanin receptors, although galanin
and galanin-like peptides do not bind the receptor with ap-
preciable affinity. In the past year, homozygosity mapping
and candidate gene analysis of large consanguineous pedi-
grees has led two groups to describe loss-of-function muta-
tions in GPR54 in association with autosomal recessive HH
(4, 5). In parallel, the independent generation and charac-
terization of a Gpr54 knockout mouse model, which shows
a phenocopy of human isolated HH, has demonstrated that
the function of GPR54 is conserved in mammals and that
GPR54 is absolutely required for the normal function of this
axis (5).
Mouse and human studies to date suggest GPR54 has a
role in the release of GnRH (5, 6), further weight having
recently been added to this hypothesis by the demonstration
that peripherally and centrally administered kisspeptins can
provoke robust LH and FSH release (6–8). However, it is not
yet clear whether kisspeptins subserve primarily autocrine,
paracrine, or endocrine function. Intriguingly, the putative
endogenous GPR54 ligand, an amidated proteolytic product
of full-length kisspeptin-1, sometimes called metastin (12–
14), is normally present only at lowpicomolar concentrations
in plasma but rises some 10,000-fold by the end of pregnancy
(15). Both kisspeptin-1 and GPR54 are widely expressed,
with the highest GPR54 expression being reported in pla-
centa, brain, pituitary, pancreas, and spinal cord,whereas the
highest kisspeptin-1 expression is seen in placenta, with sig-
nificant levels also in pancreas and testis (12–14). This wide-
spread expression implies a more complex role for GPR54/
kisspeptin-1 than appreciated at present, and studies of
humans harboring loss-of-function mutations are likely to
make a valuable contribution to further elucidation of its
biology.
The current report adds to the spectrumof loss-of-function
mutations in GPR54. Previous studies reported five different
mutations in four families or individuals with HH. Homozy-
gosity for a 155-bp deletion spanning the splice acceptor site
of the intron 4-exon 5 junction and part of exon 5 was de-
tected in a consanguineous pedigree with five affectedmem-
bers (4). This homozygous deletion cosegregated with HH in
this family and was inferred to result in loss of receptor
function due to truncation of the coding sequence at residue
267. A second rare sequence variant, this time a missense
mutation, L102P, immediately after the second transmem-
brane helix, was also found in one family on screening three
other kindredswith familial HH.However, no cosegregation
or functional studies of this mutant were reported (4). An-
other report of loss of function of GPR54 in patients with HH
described both a homozygous L148S point mutation in a
conserved region of the second intracellular loop in a con-
sanguineous Saudi kindred and compound heterozygosity
for two mutations, R331X and X399R, in an unrelated Afro-
Caribbean patient, which were proven to result in significant
loss of GPR54 signaling in vitro (5). In total, the published
reports to date describe the screening of 68 unrelated pro-
bands with normosmic HH (five familial; 63 idiopathic) and
normal GnRH receptor gene sequence, of whom three had
two proven hypofunctional or nonfunctional GPR54 alleles
(two familial; one idiopathic). This is consistent with our
finding of one such patient in a further 17 studied (three
familial; 14 idiopathic: Table 1). Cumulative results now sug-
gest that, in those in which GnRHR coding sequence muta-
tions have been ruled out, around 2–3% (two of 77 studied)
of idiopathic normosmicHHmay be accounted for byGPR54
loss-of-function mutations, whereas at present 25% (two of
eight studied) of familial cases have been found to have such
FIG. 2. Response of GPR54 variants to stim-
ulation with kisspeptin 112–121 decapeptide.
RFU, Relative fluorescence units. Experi-
ments were performed in duplicate on 2 con-
secutive days, and SDs are indicated. Dose-
response curves were generated using a
four-parameter logistic equation. The result-
ing parameters and correlation coefficients
are indicated.
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mutations. However, no GPR54mutations were identified in
patients or families with CDP alone.
It is highly likely, although not conclusively proven, that
compound heterozygosity for the C223R and R297L variants
is the cause of the idiopathic HH seen in our proband. C233R
is severely defective in its signaling capability and is not seen
as a common variant in the Afro-Caribbean population. In
contrast, the effect of the R297Lmutation on signaling is only
modest, although highly statistically significant, when stud-
ied in vitro. However it is a highly conserved residue in
mammalian GPR54 and was not found in an ethnically
matched control population. It is likely that its effects in
combination with the severe dysfunction of the C233R vari-
ant are sufficient to lead to a clinical phenotype.
Although the patient we describe is not yet beyond the age
of normal puberty, he had sufficient clinical and biochemical
evidence of HH to warrant induction of puberty at an age
appropriate for his peer group. For example, bilateral cryp-
torchidism and micropenis were noted at birth; he had un-
detectable gonadotropins at 2 months of age [when the
hypothalamic-pituitary-gonadal axis is usually relatively ac-
tive (16)]; and his response to exogenous GnRH stimulation
at the age of 10 yr was poor. In addition, his testosterone
response to stimulation for 3 wk with hCG at this time was
relatively low. Although this may reflect the tropic effect of
prolonged gonadotropin insufficiency or delayed orchi-
dopexy, it remains possible that theGPR54/kisspeptin-1 sys-
tem could have a direct effect on testicular function, too. Of
note, GPR54 mRNA has previously been detected, albeit at
low levels, in human testis (13, 14). Thus, the effect of re-
combinant gonadotropin stimulation on the induction of fer-
tility in patients with GPR54 gene mutations remains to be
seen.
The present report uses a GPR54 signaling assay that is
substantially more sensitive than that used to evaluate pre-
vious pathogenic mutations. The assay reported originally
was based on transient expression of GPR54, stimulation
with kisspeptin-1 112–121 decapeptide, and determination of
the generation of inositol triphosphate. Stimulation of ino-
sitol triphosphate levels was seen only at around 10 nm
kisspeptin-1 112–121 for wild-type GPR54, with maximal
activity around 100 m (3). In contrast, this study employed
real-time measurements of calcium flux, similar in principle
to those previously used in the identification of kisspeptin as
a bona fide GPR54 ligand (12–14). As seen in Fig. 2, this assay
detects signaling at subnanomolar concentrations of the
kisspeptin decapeptide, and activity is maximal at around
100 nm, some 2–3 orders of magnitude lower than the ligand
concentration required to maximize inositol triphosphate
generation in the previous assay.
In the absence of functional assessment of the GPR54
L102P variant, GPR54 C223R and R297L are the second- and
third-point mutations after L148S reported to result in im-
paired GPR54 function because the 155-bp deletion, R331X,
and X399R are all likely to have resulted in loss of function
largely through impaired expression of mRNA and/or pro-
tein product. The new mutations may thus prove more in-
formative with respect to understanding of the molecular
determinants of GPR54 signaling. The dramatic loss of func-
tion of GPR54 C223R is unsurprising in view of likely dis-
ruption of the fifth transmembrane helix. Indeed, it will be
of interest to establish whether receptor protein is expressed
at wild-type level at the plasma membrane and, if so,
whether ligand binding is preserved. R297L is situated in the
final extracellular loop of GPR54 in a slightly less conserved
region, and its effect on signaling is consequently relatively
mild in vitro. It remains to be determined whether its addi-
tional loss of function in vivo is due to inefficient receptor
synthesis or processing. Nevertheless, the dose-response
characteristics of this mutation raise the possibility that su-
praphysiological doses of exogenous kisspeptin or an analog
could be used to restore GnRH pulsatility and possibly fer-
tility in this patient. A similar approach, using high doses of
GnRH, has been used to induce ovulation in a woman with
a partial loss-of-functionmutation in theGnRH receptor (17).
Furthermore, because we have not been able to establish
whether the father of the propositus is indeed heterozygous
for the C223R variant, we cannot conclude on phenotypic
grounds that heterozygosity for this variant is not clinically
expressed. Thus, dominant negativity of GPR54 C223R, or an
interaction between C223R and R297L, cannot be formally
excluded. However, although there are precedents for dom-
inant-negative GPR mutations, often based on receptor
misrouting or G protein sequestration, the dominant nega-
tivity is often more apparent in vitro than in vivo (18), and we
believe it more likely in this case that it is the cumulative loss
of function of the two variants that is responsible for the
clinical phenotype.
In addition to identifying and characterizing two rare se-
quence variants in the GPR54 gene, we have also confirmed
two previously described SNPs (Table 3A). One of these is
nonsynonymous, with an alternative histidine to leucine
change encoded in the cytoplasmic tail. A third SNP recorded
in the dbSNP database was not confirmed (1155GA;
rs3746147). Analysis ofKISS1 revealed four single nucleotide
polymorphisms, three nonsynonymous, and one not previ-
ously recorded. In addition, an insertional polymorphism
that leads to truncation of the kisspeptin-1 protein product
by seven amino acids was also confirmed (Table 3B). Once
again, a further SNP recorded in the dbSNPdatabasewas not
confirmed (287CG; rs1132112). All three nonsynonymous
KISS1 sequence variants lead to amino acid changes in the
amino-terminal part of the molecule. This is not directly
involved in signaling but is likely to contribute to the reg-
ulation of processing and secretion of the active peptide. We
have documented the frequency of occurrence of these vari-
ants in our study population and also in 180 Caucasian con-
trol chromosomes. This information could be used in future
to guide case control studies looking at either indices of
reproductive function or fertility or possibly indices of tumor
invasion or metastasis in patients with malignancy, in view
of the considerable interest in KISS1 as a metastasis-
suppressing gene.
In summary, we have described two novel missense mu-
tations in the G protein-coupled receptor GPR54 that result
in impaired kisspeptin-1 stimulation of calcium flux. Com-
pound heterozygosity for these mutations is associated with
HH, detected at birth in the proband due to bilateral cryp-
torchidism and micropenis. Although not common, loss-of-
1854 J Clin Endocrinol Metab, March 2005, 90(3):1849–1855 Semple et al. • Hypogonadism due to GPR54 Mutations
functionmutations in GPR54 appear to be a significant cause
of HH in patients from diverse ethnic backgrounds.
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